Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/111825
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pires, Patrícia C. | - |
dc.contributor.author | Paiva-Santos, Ana Cláudia | - |
dc.contributor.author | Veiga, Francisco | - |
dc.date.accessioned | 2024-01-11T11:16:37Z | - |
dc.date.available | 2024-01-11T11:16:37Z | - |
dc.date.issued | 2023-10-08 | - |
dc.identifier.issn | 1424-8247 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/111825 | - |
dc.description.abstract | Psychiatric and neurodegenerative disorders are amongst the most prevalent and debilitating diseases, but current treatments either have low success rates, greatly due to the low permeability of the blood-brain barrier, and/or are connected to severe side effects. Hence, new strategies are extremely important, and here is where liposome-derived nanosystems come in. Niosomes, transfersomes, and ethosomes are nanometric vesicular structures that allow drug encapsulation, protecting them from degradation, and increasing their solubility, permeability, brain targeting, and bioavailability. This review highlighted the great potential of these nanosystems for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorder, anxiety, and depression. Studies regarding the encapsulation of synthetic and natural-derived molecules in these systems, for intravenous, oral, transdermal, or intranasal administration, have led to an increased brain bioavailability when compared to conventional pharmaceutical forms. Moreover, the developed formulations proved to have neuroprotective, anti-inflammatory, and antioxidant effects, including brain neurotransmitter level restoration and brain oxidative status improvement, and improved locomotor activity or enhancement of recognition and working memories in animal models. Hence, albeit being relatively new technologies, niosomes, transfersomes, and ethosomes have already proven to increase the brain bioavailability of psychoactive drugs, leading to increased effectiveness and decreased side effects, showing promise as future therapeutics. | pt |
dc.language.iso | eng | pt |
dc.publisher | MDPI | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | Alzheimer’s disease | pt |
dc.subject | anxiety | pt |
dc.subject | brain bioavailability | pt |
dc.subject | depression | pt |
dc.subject | ethosomes | pt |
dc.subject | intranasal | pt |
dc.subject | niosomes | pt |
dc.subject | Parkinson’s | pt |
dc.subject | schizophrenia | pt |
dc.subject | transfersomes | pt |
dc.title | Liposome-Derived Nanosystems for the Treatment of Behavioral and Neurodegenerative Diseases: The Promise of Niosomes, Transfersomes, and Ethosomes for Increased Brain Drug Bioavailability | pt |
dc.type | article | - |
degois.publication.firstPage | 1424 | pt |
degois.publication.issue | 10 | pt |
degois.publication.title | Pharmaceuticals | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3390/ph16101424 | pt |
degois.publication.volume | 16 | pt |
dc.date.embargo | 2023-10-08 | * |
uc.date.periodoEmbargo | 0 | pt |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.openairetype | article | - |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.cerifentitytype | Publications | - |
crisitem.author.orcid | 0000-0003-0036-4894 | - |
crisitem.author.orcid | 0000-0003-2710-6000 | - |
crisitem.author.orcid | 0000-0002-1041-0068 | - |
Appears in Collections: | FFUC- Artigos em Revistas Internacionais |
Files in This Item:
Page view(s)
72
checked on Aug 28, 2024
Download(s)
55
checked on Aug 28, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License